Business
Covalon Reports Strong Sequential Quarter on Quarter and Trailing Twelve Months Performance
Sequential QoQ Revenue Growth of 10.4%, Adjusted EBITDA Growth of 52% Trailing Twelve Mon...
About this update from Covalon Technologies Ltd.
[{"type":"text","content":"Covalon Reports Strong Sequential Quarter on Quarter and Trailing Twelve Months Performance\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl1 { padding-left: 5px }\n.bwpadr0 { padding-right: 0px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwuline { text-decoration: underline }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth1 { width: 1% }\n.bwwidth100 { width: 100% }\n.bwwidth12 { width: 12% }\n.bwwidth13 { width: 13% }\n.bwwidth2 { width: 2% }\n.bwwidth48 { width: 48% }\n \n\n\n\n\n\n Sequential QoQ Revenue Growth of 10.4%, Adjusted EBITDA Growth of 52%\n \n\n\n\n Trailing Twelve Months Revenue Growth of 13%, Adjusted EBITDA Growth of 116%\n \n\n\n\n\n\n Covalon Technologies Ltd. (the \"Company\" or \"Covalon\") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2025 third quarter results for the period ended June 30, 2025, along with a number of important recent achievements and highlights.\n \n\n Brent Ashton, Covalon’s Chief Executive Officer, reported,\n \n “The Covalon team has made numerous advancements on our strategic priorities in the past few months. This solid progress is enabling customer wins, exciting new partnerships, and important market development activities that will drive increased use of Covalon’s life-saving products.\n \n\n\n\n In our most recent quarter, Covalon delivered sequential quarter-on-quarter (FY’25-Q2 to FY’25-Q3) growth as follows:\n \n\n\n\n\n Grew Revenue by 10.4% to $8.4 million\n \n\n\n\n Grew Adjusted Gross Margin by 40 bps to 55.6%\n \n\n\n\n Grew Adjusted EBITDA by 52% to $0.9 Million\n \n\n\n\n\n For our most recent trailing twelve months, Covalon has:\n \n\n\n\n\n Grown Revenue by 13% (more than double the underlying growth rate of the market)\n \n\n\n\n Grown Gross Pr...